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Although neuromuscular clinical features often dominate the clinical presentation of mitochondrial disease due to the m.3243A>G
mitochondrial DNA (mtDNA) mutation, many patients develop cardiac failure, which is often overlooked until it reaches an advanced
stage. We set out to determine whether cardiac complications are suﬃciently common to warrant prospective screening in all mutation
carriers. Routine clinical echocardiography and 3 Tesla cardiac MRI were performed on ten m.3243A>G mutation carriers and
compared to age and gender matched controls, with contemporaneous quadriceps muscle biopsies to measure respiratory chain activity
and mtDNA mutation levels. Despite normal echocardiography, all ten m.3243A>G mutation carriers had evidence of abnormal cardiac
function on MRI. The degree of cardiac dysfunction correlated with the percentage level of mutant mtDNA in skeletal muscle.
Sub-clinical cardiac dysfunction was a universal ﬁnding in this study, adding weight to the importance of screening for cardiac
complications in patients with m.3243A>G. The early detection of cardiac dysfunction with MRI opens up opportunities to prevent
heart failure in these patients through early intervention.
 2012 Elsevier B.V.
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Neurological features usually dominate the clinical pre-
sentation of patients harbouring the m.3243A>G mito-
chondrial DNA (mtDNA) mutation; with migraine,
encephalopathy, seizures, stroke-like episodes, deafness,
ophthalmoplegia and myopathy all being common.
Although well recognised in advanced cases [1], cardiomy-0960-8966 2012 Elsevier B.V.
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Open access under CC BY license.opathy is often overlooked, despite being a major cause of
morbidity and mortality [2,3], and it may explain the
increased rate of sudden unexpected death observed in
Finnish patients harbouring m.3243A>G [4]. Using rela-
tively insensitive 2D-echocardiography, left-ventricular
hypertrophy was been detected in 56% of cases [2], raising
the possibility that cardiac dysfunction is major feature of
the disorder potentially amenable to early treatment to pre-
vent cardiac failure [5]. To address this issue, we used car-
diac magnetic resonance imaging (MRI) to determine the
prevalence of cardiac dysfunction in m.3243A>G mutation
carriers, with contemporaneous genetic and biochemical
studies on skeletal muscle to elucidate the mechanism.
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We studied ten m.3243A>G mutation carriers (ﬁve
male, ﬁve female, mean age 42.5 ± SD 9 years). Tables 1
and 2 shows the clinical and laboratory data, including
co-morbidities and medication), and sixteen healthy age
matched controls (eight male, eight female, mean age
41.6 ± SD 15 years). No signiﬁcant abnormalities were
found on electrocardiography (ECG) or 2D-echocardiog-
raphy in either group. Systolic and diastolic blood pressure
was normal. Nine m.3243A>G mutation carriers under-
went a left vastus lateralis skeletal muscle needle biopsy.
Respiratory chain complex activities, and the level of
m.3243A>G mutation were determined in each biopsy as
described [6], along with the mutation load in urinary epi-
thelium and blood when available.
3-Tesla ECG-gated cardiac MRI was performed using a
six-channel cardiac coil on supine subjects (Philips Intera
Achieva, Best, NL). Structural evaluation included left
ventricular (LV) mass relative to body surface area, ejec-
tion fraction, end-systolic and end-diastolic volumes. The
eccentricity ratio was calculated as the ratio of LV mass
to end-diastolic volume and an increase in this parameterTable 1
Clinical data for the patients harbouring m.3243A>G. It was not possible to
No. Age (years) Sex Clinical features
1 55 M Deafness, diabetes,
2 48 M Deafness, diabetes,
3 46 M Deafness, hc, seizure
4 34 F Deafness, constipati
5 44 M Migraine, constipati
6 42 F Deafness, diabetes, h
7 55 F Constipation, ha; as
8 30 F Deafness, diabetes, h
9 31 M None
10 40 F Deafness, diabetes
Key: ha = headaches, hc = hypercholesterolaemia, ht = hypertension, AC
ln = insulin, a = aspirin, m = metformin, c = carbamazepine, f = ﬂunarazine,
Table 2
Molecular genetic and biochemical data for the patients harbouring m.3243A
activities were measured as previously described.
No. 3243A>G mutation load I/mg
SKM UE BLD
1 62 66 nd 0.62
2 81 nd nd 0.28
3 26 82 28 1.35
4 67 80 26 0.64
5 46 48 5 0.62
6 52 nd nd 1.17
7 60 20 9 1.12
8 93 86 3 0.20
9 24 34 7 1.53
10 73 57 21 –
The percentage level of m.3243A>G and respiratory chain complex activities we
biopsy from subject 10. CS = citrate synthase activity, nd = not determined. Swas interpreted as evidence of concentric remodelling.
Cardiac tagging was used to evaluate function measured
as torsion and regional myocardial strains: these include
the torsion-to-endocardial strain ratio, a measure of the
relative contribution of the endocardial and epicardial con-
tractions to systole; and radial thickening, the percentage
increase in average wall thickness from end-diastole to sys-
tole (Detailed MRI methods described on-line). Written
informed consent was obtained from all participants and
institutional ethics was obtained.
3. Results
All m.3243A>G patients had structural and functional
cardiac abnormalities on MRI when compared to age-
matched controls (Table 3. Online videos). These included,
increased LV index (74 g/m2 vs. 59 g/m2, p = 0.001),
reduced end systolic (36 ml vs. 61 ml, p = 0.0005) and dia-
stolic volume (103 ml vs. 143 ml, p = 0.002), increased peak
torsion (7.3 vs. 6.0 , p = 0.02) and an increased eccentric-
ity ratio (1.19 g/ml vs 0.74 g/ml, p = 0.001, Fig. 1), indica-
tive of cardiac remodelling. The percentage level of
m.3243A>G mutation in skeletal muscle correlated withobtain a muscle biopsy from subject 10.
Medication Echo LVEF (%)
ht, ha ACEi, a, m, In, St 66
ha ACEi, St, In 70
s, SLEs. c, a, ACEi, St 55
on, ha – >60
on f, a 61
t, SLEs z, ACEi >55
thma – >55
t, hcl, SLEs. pr, St, c, In, le >60
– 60
– n/a
Ei = angiotensin converting enzyme inhibitor, St = statin ± ezetmibe,
z = Na val, pr = propanolol, le = levemenre. SLEs: stroke-like episodes.
>G. The percentage level of m.3243A>G and respiratory chain complex
II/mg III/mg IV/mg CS/mg
3 1.017 5.613 7.891 6.393
4 0.881 8.185 4.966 7.128
4 2.061 17.294 21.440 9.116
5 3.237 21.716 17.507 11.628
6 1.344 8.861 9.589 6.421
6 4.710 34.082 28.429 21.743
6 2.367 14.938 19.049 13.412
7 1.807 13.000 4.939 18.911
0 2.155 16.711 16.024 12.584
– – – –
re measured as previously described. It was not possible to obtain a muscle
KM = skeletal muscle, UE = urinary epithelium, BLD = blood.
Table 3
Cardiac morphology and function parameters for controls and mutation carriers. LV = left ventricle.
Parameter Controls m.3243A>G p value
Age (years) 41.6 ± 15 42.5 ± 9 ns
Heart rate (bpm) 61 ± 13 71 ± 12 ns
Systolic blood pressure (mm Hg) 128 ± 13 130 ± 14 ns
Diastolic blood pressure (mm Hg) 76 ± 10 83 ± 10 ns
Height (cm) 171 ± 11 165 ± 11 ns
Weight (kg) 75 ± 10 63 ± 16 0.02
Body Surface Area (BSA, m2) 1.8 ± 0.1 1.6 ± 0.2 ns
LV mass and global systolic function
LV mass (g) 106.7 ± 20.4 119.7 ± 29.6 ns
LV index [LV mass/BSA] (g/m2) 59.3 ± 9.5 73.7 ± 9.9 0.001
Stroke volume (ml) 82 ± 15 67 ± 16 0.02
End-diastolic volume (ml) 143.0 ± 32.0 103.1 ± 23.3 0.002
End-systolic volume (ml) 61.0 ± 18.7 36.2 ± 10.8 0.0005
Ejection fraction (%) 58 ± 5 65 ± 6 0.004
Eccentricity ratio [LV mass/EDV] (g/ml) 0.74 ± 0.11 1.19 ± 0.30 0.001
LV strains
Longitudinal shortening (%) 18.1 ± 2.8 14.5 ± 4.0 0.01
Peak torsion (degrees) 6.0 ± 1.4 7.3 ± 1.3 0.02
Peak circumferential strain (%) 17.8 ± 2.7 17.5 ± 2.7 ns
Radial thickening (%) 59 ± 20 65 ± 23 ns
Torsion to endocardial strain ratio (rad) 0.49 ± 0.13 0.57 ± 0.14 ns
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Fig. 1. For m.3243A>G and control groups – (a) left ventricular index (left ventricular mass/body surface area), (b) eccentricity ratio. Within the
m.3243A>G group, mutation load correlates with (c) torsion to endocardial strain ratio and (d) radial thickening.
594 K.G. Hollingsworth et al. / Neuromuscular Disorders 22 (2012) 592–596the decrease in respiratory chain complex I activity (j =
0.71, p = 0.01); and both muscle mutation load and
complex I activity correlated with the torsion to endocar-
dial strain ratio (j = 0.71, p < 0.05 and j = 0.73, p <
0.03, respectively), and with reduced radial thickening
(j = 0.80, p = 0.01, Fig. 1).4. Discussion
We found structural and functional cardiac abnormali-
ties in all of the m.3243A>G patients we studied. The
major ﬁndings were: (1) concentric left ventricular hyper-
trophy in the absence of systemic hypertension; and (2) a
K.G. Hollingsworth et al. / Neuromuscular Disorders 22 (2012) 592–596 595re-orientation of myocardial strains with reduced longitu-
dinal shortening and increased torsion. These ﬁndings indi-
cate that sub-clinical cardiomyopathy is common in
m.3243A>G patients, and may be a universal ﬁnding.
Although the majority of subjects in our study had clinical
features of mtDNA disease, one was an asymptomatic
carrier who also had abnormal cardiac function on MRI.
Given previous reports of progressive cardiac hypertrophy
leading to irreversible dilated cardiomyopathy in
m.3243A>G patients [7], our observations re-enforce the
importance of cardiac monitoring in all m.3243A>G muta-
tion carriers. Cardiac MRI provides a sensitive method of
detecting early cardiac dysfunction, complementing echo-
cardiography. Early intervention may reduce cardiac
remodelling in m.3243A>G patients and thus delay left
ventricular failure, although this needs to be prospectively
studied.
Despite known diﬀerences in tissue mutation load, we
observed a correlation between the percentage level of
m.3243A>G and complex I activity in skeletal muscle,
and several key cardiac measures of early cardiac dysfunc-
tion. When taken together, these observations support a
central role for the genetic and biochemical defect in the
pathogenesis of the cardiomyopathy, rather than an indi-
rect mechanism through reduced physical ﬁtness or co-
morbidity related to the diabetes known to occur in
m.3243A>G carriers.
It remains intriguing that the two lowest muscle muta-
tion levels were observed in a 31 year old patient without
symptoms (m.3243A>G = 24%) and in a 46 year old
patient with a severe MELAS phenotype (m.3243A>G =
26%). These ﬁndings reﬂect the known poor correlation
between muscle mutation load and neurological pheno-
type; and contrast with the correlation that we observed
between skeletal muscle mutation load and the degree of
cardiac dysfunction. By inference, this implies that muta-
tion load in myocardium is closely related to mutation load
in skeletal muscle, and that the consequences of a given
mutation level are similar in both cardiac and skeletal mus-
cle. The same does not appear to be the case for the central
nervous system, where there is a much more diverse range
of cell types of diﬀerent embryological origins, each
responding to a given level of m.3243A>G to diﬀering
degrees, and contributing to the combined neurological
phenotype in diﬀerent ways. The lack of any correlation
between blood mutation levels and the cardiac phenotype
is not surprising, given that m.3243A>G in blood decreases
with age [8], unlike other tissues [9].
Our observations also suggest that measures aimed at
reducing mutation load or improving complex I activity
are likely to be beneﬁcial for the cardiomyopathy in
m.3243A>G patients. Although there are currently no
known methods of reducing cardiac mutation load, it is
conceivable that “gene shifting” techniques currently being
explored in skeletal muscle could be of beneﬁt [10]. This
would involve the delivery or local activation of cardiomy-
ocyte precursors potentially harbouring a lower mutationload. An alternative approach could involve drugs known
to increase mitochondrial biogenesis which could improve
both the genetic and biochemical defect in a similar way
to aerobic exercise in skeletal muscle [11]. Interestingly,
we saw no correlation between m.3243A>G mutation load,
complex I activity, or cardiac dysfunction and the speciﬁc
enzyme activities of complex II and citrate synthase (Table
2). These enzymes are considered to be markers of mito-
chondrial proliferation and biogenesis, suggesting that
compensatory mitochondrial proliferation had not been
activated in the skeletal muscle of the patients described
here, despite the complex I defect. Finally, treatment with
anti-oxidant drugs provides hope of treatment in the short
term. The anti-oxidant properties of idebenone may
explain the beneﬁcial eﬀects of this drug on the cardiomy-
opathy in Friedreich’s ataxia, which also has a mitochon-
drial basis. The approach we describe here provides an
objective method for assessing the eﬃcacy of novel treat-
ments in patients with m.3243A>G. This will hopefully
lead to the ﬁrst cardioprotective therapy for primary mito-
chondrial disease.Acknowledgements
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